Has Your Vehicle Been Involved In A Safety Recall?

Consumers Have The Ability To Check To See If Their Vehicle Is Involved In A Safety Recall 

Kehoe Law Firm, P.C. is making consumers aware that the National Highway Traffic Safety Administration (“NHTSA”) provides a Vehicle Identification Number Search Tool (“VIN Search Tool”) which allows vehicle owners to determine if a specific vehicle needs to be repaired as part of a safety recall. 

Vehicle Identification Number (“VIN”) & The VIN Search Tool

Vehicle owners can look at the lower left side of their car’s windshield for the unique, 17-character VIN. The VIN is also located on a car’s registration card, and it may also be printed on a vehicle insurance card.

The VIN Search Tool Will Show
  • An unrepaired vehicle affected by a vehicle safety recall in the past 15 calendar years;
  • Vehicle safety recalls from major light auto automakers, motorcycle manufacturers, and some medium/heavy truck manufacturers.
The VIN Search Tool Will Not Show
  • A vehicle with a repaired safety recall. If a vehicle has no unrepaired recalls, the message: “0 Unrepaired recalls associated with this VIN” will appear;
  • Manufacturer customer service or other nonsafety recall campaign;
  • International vehicles;
  • There may be a delay with very recently announced safety recalls for which not all VINs have been identified. VINs are added continuously and should be checked regularly;
  • Safety recalls that are more than 15 years old (except where a manufacturer offers more coverage);
  • Safety recalls conducted by small vehicle manufacturers, including some ultra-luxury brands and specialty applications.
How To Check A Vehicle’s VIN For Safety Issues & Recalls

To check a vehicle affected by a safety recall, please click VIN Search Tool and enter the vehicle’s 17-character VIN.

Additional Information About Motor Vehicle Safety Defects And Recalls

Please click “What Every Vehicle Owner Should Know,” for more information about motor vehicle safety defects and recalls, including information about how and why recall campaigns are initiated, as well as one’s rights and responsibilities when a vehicle or item of motor vehicle equipment is recalled.

Do You Think You Have Experienced An Automotive/Vehicle Defect? Is Your Vehicle The Subject Of A Defect Investigation?

If you have been affected by a vehicle problem, please contact Kehoe Law Firm, P.C. by completing the form on the right, or by sending an e-mail to [email protected], to help you determine whether your vehicle is the subject of a defect investigation or to request a free, no-obligation evaluation of potential legal claims.

Source: NHTSA.gov

Kehoe Law Firm, P.C.

bluebird bio Investors Who Have Suffered Significant Losses

Class Action Lawsuit Filed On Behalf Of bluebird bio Investors – BLUE Investors With Losses Greater Than $100,000 Encouraged To Contact Kehoe Law Firm, P.C. 

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of bluebird bio, Inc. (“bluebird” or the “Company”) (NASDAQ: BLUE) to determine whether the Company engaged in securities fraud or other unlawful business practices. 

INVESTORS WHO PURCHASED, OR OTHERWISE ACQUIRED, BLUEBIRD SECURITIES BETWEEN MAY 11, 2020 AND NOVEMBER 4, 2020, BOTH DATES INCLUSIVE (THE “CLASS PERIOD”), AND SUFFERED LOSSES GREATER THAN $100,000 ARE ENCOURAGED TO COMPLETE KEHOE LAW FIRM’S SECURITIES CLASS ACTION QUESTIONNAIRE OR CONTACT MICHAEL YARNOFF, ESQ., (215) 792-6676, EXT. 804, [email protected], [email protected], [email protected], TO DISCUSS THE SECURITIES INVESTIGATION OR POTENTIAL LEGAL CLAIMS.  

On February 12, 2021, a class action lawsuit was filed against bluebird in United States District Court, Eastern District of New York.

Throughout the Class Period, according to the class action complaint, the bluebird Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies.

The bluebird Defendants, allegedly, made false and/or misleading statements and/or failed to disclose that (i) data supporting bluebird’s U.S. Biologics Licensing Application (“BLA”) submission for LentiGlobin for sickle cell disease (“SCD”) was insufficient to demonstrate drug product comparability; (ii) Defendants downplayed the foreseeable impact of disruptions related to the COVID-19 pandemic on the Company’s BLA submission schedule for LentiGlobin for SCD, particularly with respect to manufacturing; (iii) as a result of the foregoing, it was foreseeable that the Company would not submit the BLA for LentiGlobin for SCD in the second half of 2021; and (iv) as a result, bluebird’s public statements were materially false and misleading at all relevant times.

Kehoe Law Firm, P.C.